MacroGenics, Inc. (MGNX)

NASDAQ: MGNX · IEX Real-Time Price · USD
3.52
+0.10 (2.92%)
Jul 7, 2022 1:24 PM EDT - Market open
2.92%
Market Cap 215.89M
Revenue (ttm) 71.67M
Net Income (ttm) -217.29M
Shares Out 61.33M
EPS (ttm) -3.56
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 382,268
Open 3.44
Previous Close 3.42
Day's Range 3.41 - 3.55
52-Week Range 2.13 - 28.19
Beta 2.15
Analysts Buy
Price Target 28.90 (+721.0%)
Earnings Date Aug 4, 2022

About MGNX

MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugat... [Read more...]

Industry Biotechnology
IPO Date Oct 10, 2013
CEO Scott Koenig
Employees 427
Stock Exchange NASDAQ
Ticker Symbol MGNX
Full Company Profile

Financial Performance

In 2021, MacroGenics's revenue was $77.45 million, a decrease of -26.16% compared to the previous year's $104.88 million. Losses were -$202.12 million, 55.8% more than in 2020.

Financial Statements

Analyst Forecast

According to 18 analysts, the average rating for MGNX stock is "Buy." The 12-month stock price forecast is 28.9, which is an increase of 721.02% from the latest price.

Price Target
$28.9
(721.02% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Why MacroGenics Stock Is Skyrocketing Today

Investors like that a key insider is buying shares of the biotech.

MacroGenics to Participate in Upcoming Investor Conference

ROCKVILLE, MD, June 08, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the tr...

MacroGenics Announces Appointment of William Heiden to Board of Directors

ROCKVILLE, MD, May 23, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the tre...

Why MacroGenics Stock Is Tanking Today

Investors found plenty to dislike about the company's Q1 update.

MacroGenics (MGNX) Reports Q1 Loss, Lags Revenue Estimates

MacroGenics (MGNX) delivered earnings and revenue surprises of -28.57% and 35.46%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

MacroGenics Provides Update on Corporate Progress and First Quarter 2022 Financial Results

ROCKVILLE, Md., May 03, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the tr...

MacroGenics Announces Date of First Quarter 2022 Financial Results Conference Call

ROCKVILLE, MD, April 25, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutic...

MacroGenics to Participate in Upcoming Investor Conferences

ROCKVILLE, MD, March 03, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the t...

MacroGenics Announces Executive Promotion

ROCKVILLE, MD, Feb. 28, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the tr...

Why MacroGenics Stock Is Sinking Today

The company provided a disappointing Q4 update.

MacroGenics (MGNX) Reports Q4 Loss, Misses Revenue Estimates

MacroGenics (MGNX) delivered earnings and revenue surprises of -14.46% and 28.67%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

MacroGenics Provides Update on Corporate Progress and 2021 Financial Results

ROCKVILLE, Md., Feb. 24, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the t...

Analysts Estimate MacroGenics (MGNX) to Report a Decline in Earnings: What to Look Out for

MacroGenics (MGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

MacroGenics Announces Date of Fourth Quarter 2021 Financial Results Conference Call

ROCKVILLE, MD, Feb. 14, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics...

Synaffix, MacroGenics Ink Pact For Next Generation Antibody-Drug Conjugates

Synaffix BV has entered into a technology agreement with MacroGenics Inc MGNX. Get the Inside Access Traders Are Using to Profit More and Win Bigger.

MacroGenics (MGNX) Reports Q3 Loss, Misses Revenue Estimates

MacroGenics (MGNX) delivered earnings and revenue surprises of -36.51% and -60.41%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

MacroGenics Provides Update on Corporate Progress and Third Quarter 2021 Financial Results

ROCKVILLE, Md., Nov. 02, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutic...

MacroGenics Announces Date of Third Quarter 2021 Financial Results Conference Call

ROCKVILLE, MD, Oct. 26, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics...

Wall Street Analysts See a 69% Upside in MacroGenics (MGNX): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 69.5% in MacroGenics (MGNX). While the effectiveness of this highly sought-after metric is questionable, the posi...

I-Mab Announces Acceptance of IND Application from China NMPA for Phase 2 Clinical Trial of Enoblituzumab in Combinat...

SHANGHAI and GAITHERSBURG, Md., Sept. 28, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercializat...

Other symbols: IMAB

MacroGenics Shares Fall After MGC018 Data Fails To Impress At ESMO Presentation

MacroGenics Inc (NASDAQ: MGNX) announced preliminary safety and anti-tumor activity data from dose-expansion cohorts of the Phase 1 trial of MGC018. The data was presented at the 2021 European Society f...

MacroGenics Announces Preliminary Clinical Results from Phase 1 Cohort Expansion of the Ongoing MGC018 Study Presente...

ROCKVILLE, MD, Sept. 16, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutic...

MacroGenics Announces Clinical Results from Cohort A Part 1 of Phase 2/3 MAHOGANY Study of Margetuximab in Combinatio...

ROCKVILLE, MD, Sept. 16, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutic...

MacroGenics Announces Presentations at ESMO 2021 Virtual Annual Congress

ROCKVILLE, MD, Sept. 12, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutic...

MacroGenics (MGNX) Stock Jumps 8.9%: Will It Continue to Soar?

MacroGenics (MGNX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase i...